CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company’s biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. ...

CHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic value of its wholly owned real estate portfolio and announced that it is evaluating strategic monetization options to unlock shareholder value. Based on independent valuation reports, recent market data, and comparable transactions, management estimates the combined fair market value of the Company’s Cana ...

CHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic value of its wholly owned real estate portfolio and announced that it is evaluating strategic monetization options to unlock shareholder value. Based on independent valuation reports, recent market data, and comparable transactions, management estimates the combined fair market value of the Company’s Cana ...

Core Insights - Cosmos Health Inc. is expanding its retail presence in the UK by making its antimicrobial skin cleanser, C-Scrub, available through Superdrug, the second-largest beauty and health retailer in the UK [1][4]. Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group established in 2009, with a portfolio of proprietary pharmaceutical and nutraceutical brands [5]. - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices under European Good Manufacturing Practices (GMP) and is certified by the European Medicines Agency (EMA) [5]. - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, through subsidiaries in Greece and the UK [5]. Product Details - C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infection, thereby supporting effective skin hygiene [4]. - The product's availability in Superdrug's extensive retail and pharmacy network enhances Cosmos Health's market positioning in the UK [4]. Strategic Importance - The entry into Superdrug reinforces the retail momentum for C-Scrub in the UK and strengthens the company's market positioning across various retail platforms [5]. - This expansion is expected to increase brand reach and support the long-term development of Cosmos Health's broader product portfolio in the region [5].

Core Insights - Cosmos Health Inc. is expanding its retail presence in the UK by making its antimicrobial skin cleanser, C-Scrub, available through Superdrug, the second-largest beauty and health retailer in the UK [1][4]. Group 1: Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [5]. - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including C-Scrub, and operates under European Good Manufacturing Practices (GMP) [5]. - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, and has established R&D partnerships targeting major health disorders [5]. Group 2: Product Details - C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infection, supporting effective skin hygiene [4]. - The product's availability in Superdrug's extensive retail and pharmacy network enhances Cosmos Health's market positioning in the UK [4]. Group 3: Strategic Importance - The entry into Superdrug reinforces the retail momentum for C-Scrub in the UK, significantly strengthening the company's market positioning across various retail platforms [5]. - This expansion increases brand reach and supports the long-term development of Cosmos Health's broader product portfolio in the region [5].

Core Viewpoint - Cosmos Health Inc. has significantly expanded its retail presence in the UK by launching its antimicrobial skin cleanser, C-Scrub, through Tesco, the largest retailer in the UK, enhancing the product's visibility and market credibility [1][3][6]. Group 1: Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [7]. - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union through its subsidiary, Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices (GMP) [7]. - Cosmos Health also distributes a wide range of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors in Greece and the UK [7]. Group 2: Product Details - C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infection, supporting effective skin hygiene [5]. - The product's entry into Tesco represents a pivotal moment for the company, enhancing its retail presence and credibility in the market [6]. Group 3: Market Strategy - Expanding distribution through Tesco is a meaningful advancement in Cosmos Health's UK growth strategy, expected to drive continued momentum for C-Scrub as the company strengthens retail partnerships [3][5]. - The CEO of Cosmos Health highlighted that this milestone not only provides immediate growth opportunities for C-Scrub but also establishes a platform for the potential rollout of additional products from the company's portfolio in the UK and broader European markets [6].

CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a significant expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% (“C-Scrub”), is now available through Tesco, the UK’s largest retailer. Tesco is a leading multinational retail group operating across multiple markets and ranked among the top 20 retailer ...

Core Insights - Cosmos Health Inc. participated in the World Health Expo Dubai 2026, one of the largest healthcare exhibitions globally, held from February 9-12, 2026 [1][3] - The event attracted over 235,000 visitors and 4,300 exhibitors from more than 180 countries, facilitating collaboration among healthcare leaders and innovators [3] Company Highlights - Cosmos Health showcased its proprietary nutraceutical and wellness brands, particularly the Sky Premium Life® line, which is gaining traction through expanded distribution and new product introductions [4][6] - The company also highlighted other brands such as C-Scrub®, an antiseptic wash, and Mediterranation®, a luxury nutritional supplement line featuring organic herbs from the Mediterranean [5][6] - The participation at the Expo allowed Cosmos Health to raise awareness of its manufacturing capabilities and engage with potential partners and distributors [6] Strategic Goals - CEO Greg Siok emphasized the company's commitment to expanding its global footprint and strengthening strategic relationships during the Expo [7] - The company is focused on disciplined growth, brand development, and long-term value creation, with ongoing discussions for potential agreements in regions including Japan, China, and Latin America [7] Company Overview - Cosmos Health Inc., incorporated in 2009, is a diversified global healthcare group with a portfolio of proprietary pharmaceutical and nutraceutical brands [8] - The company operates under European Good Manufacturing Practices and is involved in manufacturing pharmaceuticals, food supplements, and medical devices within the EU [8] - Cosmos Health is expanding its distribution across Europe, Asia, and North America, with established offices and distribution centers in Greece and the UK [8]

CHICAGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the expansion of its digital assets program with the purchase of $500,000 of Bitcoin (BTC), underscoring the Company’s disciplined, opportunistic, and flexible approach to capital deployment. The Company’s digital assets program has so far been centered on Ethereum (ETH). While Ethereum will continue to serve as a key pi ...

Core Viewpoint - Cosmos Health Inc. continues to experience operational growth and infrastructure expansion through its subsidiary Cosmofarm, particularly in the pharmaceutical distribution sector in Greece [1]. Group 1: Customer Growth and Financial Performance - In 2025, Cosmofarm added nearly 100 new pharmacy customers, resulting in a 20% increase in its active customer base [2]. - Annual revenue per customer increased by approximately 12%, while profitability per customer improved by around 14%, attributed to enhanced route density and optimized order execution [2]. - Management anticipates that customer growth will continue at similar or higher rates in 2026 based on current onboarding activity and demand trends [2]. Group 2: Infrastructure and Automation Investments - Cosmofarm introduced three new delivery routes in the Attica region to enhance service quality and last-mile delivery performance [3]. - The company has made multi-million dollar investments in automation and logistics infrastructure, including advanced robotic systems for procurement and order fulfillment [4]. - A capital investment program of approximately $1 million is currently underway to expand robotic capacity and throughput [4]. Group 3: Revenue Potential and Operational Efficiency - The expanded ROWA and A-frame robotic picking line is expected to materially increase processing capacity and support an incremental annual revenue potential of approximately $40 million [7]. - The company is upgrading its 29,000-square-foot property in Athens to modernize office space and enhance distribution capabilities [8]. - CEO Greg Siokas emphasized that ongoing investments in automation will significantly expand capacity and support sustainable growth and long-term value creation for Cosmos Health [10].